{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:52:07Z","timestamp":1787237527976,"version":"build-2736575974"},"reference-count":44,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The broad-spectrum C-8-cyano-fluoroquinolone finafloxacin displays enhanced activity under acidic conditions. This phase II clinical study compared the efficacies and safeties of finafloxacin and ciprofloxacin in patients with complicated urinary tract infection and\/or pyelonephritis. A 5-day regimen with 800 mg finafloxacin once a day (q.d.) (FINA05) had results similar to those of a 10-day regimen with 800 mg finafloxacin q.d. (FINA10). Combined microbiological and clinical responses at the test-of-cure (TOC) visit were 70% for FINA05, 68% for FINA10, and 57% for a 10-day ciprofloxacin regimen (CIPRO10) in 193 patients (64 for FINA05, 68 for FINA10, and 61 for CIPRO10) of the microbiological intent-to-treat (mITT) population. Additionally, the clinical effects of ciprofloxacin on patients with an acidic urine pH (80% of patients) were reduced, whereas the effects of finafloxacin were unchanged. Finafloxacin was safe and well tolerated. Overall, 43.4% of the patients in the FINA05 group, 42.7% in the FINA10 group, and 54.2% in the CIPRO10 group experienced mostly mild and treatment-emergent but unrelated adverse events. A short-course regimen of 5 days of finafloxacin resulted in high eradication and improved clinical outcome rates compared to those for treatment with ciprofloxacin for 10 days. In contrast to those of ciprofloxacin, the clinical effects of finafloxacin were not reduced by acidic urine pH. Hospitalized adults were randomized 1:1:1 to finafloxacin treatment (800 mg q.d.) for either 5 or 10 days or to ciprofloxacin treatment (400 mg\/500 mg b.i.d.) for 10 days with an optional switch from intravenous (i.v.) to oral administration at day 3. The primary endpoint was the combined microbiological and clinical response at the TOC visit in the microbiological intent-to-treat population. (This study has been registered at ClinicalTrials.gov under identifier NCT01928433.)<\/jats:p>","DOI":"10.1128\/aac.02317-17","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T06:41:15Z","timestamp":1516171275000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":32,"title":["Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections"],"prefix":"10.1128","volume":"62","author":[{"given":"F.","family":"Wagenlehner","sequence":"first","affiliation":[{"name":"Justus Liebig University, Clinic of Urology, Pediatric Urology and Andrology, Gie\u00dfen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nowicki","sequence":"additional","affiliation":[{"name":"Medical University of Lodz, Department of Nephrology, Hypertension and Kidney Transplantation, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bentley","sequence":"additional","affiliation":[{"name":"MerLion Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"L\u00fcckermann","sequence":"additional","affiliation":[{"name":"MerLion Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wohlert","sequence":"additional","affiliation":[{"name":"MerLion Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Fischer","sequence":"additional","affiliation":[{"name":"MerLion Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vente","sequence":"additional","affiliation":[{"name":"MerLion Pharmaceuticals, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Naber","sequence":"additional","affiliation":[{"name":"Technical University Munich, Department of Urology, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dalhoff","sequence":"additional","affiliation":[{"name":"University Medical Center Schleswig-Holstein, Institute for Infection Medicine, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Grabe M Bartoletti R Bjerklund-Johansen TE Cai T Cek HM K\u00f6ves B Naber KG Pickard RS Tenke P Wagenlehner F Wullt B. 2015. Guidelines on urological infections. European Association of Urology guidelines vol 2015. http:\/\/uroweb.org\/wp-content\/uploads\/19-Urological-infections_LR2.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3432"},{"key":"e_1_3_2_4_2","first-page":"159","volume-title":"Quinolone antibacterial agents","author":"Gupta K","year":"2003","unstructured":"Gupta K, Naber KG, Stamm W. 2003. Treatment of urinary tract infections, p 159\u2013170. In Hooper DC, Rubinstein E (ed) Quinolone antibacterial agents, 3rd ed. ASM Press, Washington, DC."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00833-10"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq375"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00886-10"},{"key":"e_1_3_2_8_2","volume-title":"Handbook of biological data","author":"Spector WS","year":"1956","unstructured":"Spector WS (ed). 1956. Handbook of biological data. WB Saunders Company, Philadelphia, PA."},{"key":"e_1_3_2_9_2","first-page":"1153","article-title":"Urinalysis, a comprehensive review","volume":"71","author":"Simerville JA","year":"2005","unstructured":"Simerville JA, Maxted WC, Pahira JJ. 2005. Urinalysis, a comprehensive review. Am Fam Physician 71:1153\u20131162.","journal-title":"Am Fam Physician"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2015.1052401"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00832-10"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000321028"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf047"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg060"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg329"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg059"},{"key":"e_1_3_2_17_2","volume-title":"Abstr 48th Intersci Conf Antimicrob Agents Chemother (ICAAC)-Infect Dis Soc Am (IDSA) 46th Annu Meet","author":"Muller MT","year":"2008","unstructured":"Muller MT, Stubbings W, Vente A. 2008. Comparative activity between finafloxacin and other fluoroquinolones against bacterial and eukaryotic type II topoisomerases, poster F1-2046. Abstr 48th Intersci Conf Antimicrob Agents Chemother (ICAAC)-Infect Dis Soc Am (IDSA) 46th Annu Meet. American Society for Microbiology and Infectious Diseases Society of America, Washington, DC. https:\/\/idsa.confex.com\/idsa\/2008\/webprogram\/Paper25109.html."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868040-00011"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.09.002"},{"key":"e_1_3_2_20_2","unstructured":"Strote SR Klausner HA. 17 September 2007. High-dose short-course levofloxacin for complicated urinary tract infections and acute pyelonephritis. P&T Community. https:\/\/www.ptcommunity.com\/news\/2007-09-17-000000\/high-dose-short-course-levofloxacin-approved-treatment-complicated-urinary."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079907X233340"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(98)00088-0"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkf079"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(02)80099-6"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000106191.11936.64"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200421010-00005"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2003.12.005"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.15.5.519"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.12.1583"},{"key":"e_1_3_2_30_2","first-page":"103","article-title":"The reduction in duration of antibiotic therapy as a key element of antibiotic stewardship programs","volume":"1","author":"Pasquau J","year":"2015","unstructured":"Pasquau J, de Jesus ES, Sadyrbaeva S, Aznarte P, Hidalgo-Tenorio C. 2015. The reduction in duration of antibiotic therapy as a key element of antibiotic stewardship programs. J Antimicrob Agents 1:103.","journal-title":"J Antimicrob Agents"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2004.037"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/cc3757"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0480-6"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/504483"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2014.361"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-303184"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080201"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01055-0"},{"key":"e_1_3_2_39_2","volume-title":"Safety and efficacy of finafloxacin in the treatment of hospitalized patients with complicated urinary tract infections and pyelonephritis determined in a phase 2 clinical study, abstr L-1250","author":"Vente A","year":"2015","unstructured":"Vente A, Patel H, Tambyah PA, Fischer D, Stubbings W, L\u00fcckermann M, Bentley C, Labischinski H, Dalhoff A. 2015. Safety and efficacy of finafloxacin in the treatment of hospitalized patients with complicated urinary tract infections and pyelonephritis determined in a phase 2 clinical study, abstr L-1250. Abstr 55th Int Conf Antimicrob Agents Chemother, San Diego, CA, 17 to 21 September 2015."},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1155\/2005\/385768"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.03.002"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.11250\/chemotherapy1953.40.Supplement3_196"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1159\/000329520"},{"key":"e_1_3_2_44_2","volume-title":"Statistical inference","author":"Casella G","year":"1990","unstructured":"Casella G, Berger RL. 1990. Statistical inference. Brooks Cole Publishing Company, Belmont, CA."},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02325-17"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02317-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02317-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:08:26Z","timestamp":1645459706000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02317-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1128\/AAC.02317-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02317-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"2017-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02317-17"}}